
	Home Site Map Contact Links Medical News

asthma attack information

Generic medication at fraction of the cost. Asthma.
Over 500 generics available for immediate delivery. Orders can be tracked online. 10% rebate for reorders. Full refund option.
Generics at fraction of the cost. Asthma.
Over 500 generics in stock. Licensed online pharmacy. No prescription needed. 10% rebate on reorders. Orders can be tracked online.
Generic medication Low prices
Generic medication from Licensed online pharmacy FREE doctors consultation SAVE up to 70%
Best Deals For Accolate
Compare 5 Very Best sites for Accolate.
Searching Accolate?
Best 5 Results for Accolate.
Searching Accolate?
Best 5 Results for Accolate.
Accolate
Looking for Accolate?
Accolate
Looking for Accolate?
High-yield Savings Accounts
Best Rates on Savings Accounts - Find Checking Account and High Yield Savings Account and Money Market Rates.
Blinkx Video Search
World's largest video search engine. Over 26 million hours of video. Watch it all!

asthma attack information
DESCRIPTION
Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist(LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide asthma attack information. The molecular weight of zafirlukast is 575.7 and the structural formula is:

The empirical formula is: C 31 H 33 N 3 O 6 S

Zafirlukast, a fine white to pale yellow amorphous powder, is practically insolublein water asthma attack information. It is slightly soluble in methanol and freely soluble in tetrahydrofuran,dimethylsulfoxide, and acetone asthma attack information.

ACCOLATE is supplied as 10 and 20 mg tablets for oral administration asthma attack information.

Inactive Ingredients: Film-coated tablets containing croscarmellose sodium,lactose, magnesium stearate, microcrystalline cellulose, povidone, hypromellose,and titanium dioxide asthma attack information.

CLINICAL PHARMACOLOGY
Mechanism of Action
Zafirlukast is a selective and competitive receptor antagonist of leukotrieneD 4 and E 4 (LTD 4 and LTE 4 ), components of slow-reacting substance of anaphylaxis(SRSA) asthma attack information. Cysteinyl leukotriene production and receptor occupation have been correlatedwith the pathophysiology of asthma, including airway edema, smooth muscle constriction,and altered cellular activity associated with the inflammatory process, whichcontribute to the signs and symptoms of asthma asthma attack information. Patients with asthma were foundin one study to be 25-100 times more sensitive to the bronchoconstricting activityof inhaled LTD 4 than nonasthmatic subjects asthma attack information.

In vitro studies demonstrated that zafirlukast antagonized the contractileactivity of three leukotrienes (LTC 4 , LTD 4 and LTE 4 ) in conducting airwaysmooth muscle from laboratory animals and humans asthma attack information. Zafirlukast prevented intradermalLTD 4 -induced increases in cutaneous vascular permeability and inhibited inhaledLTD 4 -induced influx of eosinophils into animal lungs asthma attack information. Inhalational challengestudies in sensitized sheep showed that zafirlukast suppressed the airway responsesto antigen; this included both the early- and late-phase response and the nonspecifichyperresponsiveness asthma attack information.

In humans, zafirlukast inhibited bronchoconstriction caused by several kindsof inhalational challenges asthma attack information. Pretreatment with single oral doses of zafirlukastinhibited the bronchoconstriction caused by sulfur dioxide and cold air in patientswith asthma asthma attack information. Pretreatment with single doses of zafirlukast attenuated the early-and late-phase reaction caused by inhalation of various antigens such as grass,cat dander, ragweed, and mixed antigens in patients with asthma asthma attack information. Zafirlukastalso attenuated the increase in bronchial hyperresponsiveness to inhaled histaminethat followed inhaled allergen challenge asthma attack information.

Clinical Pharmacokinetics and Bioavailability:
Absorption
Zafirlukast is rapidly absorbed following oral administration asthma attack information. Peak plasma concentrationsare generally achieved 3 hours after oral administration asthma attack information. The absolute bioavailabilityof zafirlukast is unknown asthma attack information. In two separate studies, one using a high fat andthe other a high protein meal, administration of zafirlukast with food reducedthe mean bioavailability by approximately 40% asthma attack information.

Distribution
Zafirlukast is more than 99% bound to plasma proteins, predominantly albumin asthma attack information. The degree of binding was independent of concentration in the clinically relevantrange asthma attack information. The apparent steady-state volume of distribution (V SS /F) is approximately70 L, suggesting moderate distribution into tissues asthma attack information. Studies in rats using radiolabeledzafirlukast indicate minimal distribution across the blood-brain barrier asthma attack information.

Metabolism
Zafirlukast is extensively metabolized asthma attack information. The most common metabolic products arehydroxylated metabolites which are excreted in the feces asthma attack information. The metabolites ofzafirlukast identified in plasma are at least 90 times less potent as LTD 4receptor antagonists than zafirlukast in a standard in vitro test of activity asthma attack information. In vitro studies using human liver microsomes showed that the hydroxylated metabolitesof zafirlukast excreted in the feces are formed through the cytochrome P4502C9 (CYP2C9) pathway asthma attack information. Additional in vitro studies utilizing human liver microsomesshow that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymesat concentrations close to the clinically achieved total plasma concentrations(see Drug Interactions ) asthma attack information.

Excretion
The apparent oral clearance (CL/f) of zafirlukast is approximately 20 L/h asthma attack information. Studiesin the rat and dog suggest that biliary excretion is the primary route of excretion asthma attack information. Following oral administration of radiolabeled zafirlukast to volunteers, urinaryexcretion accounts for approximately 10% of the dose and the remainder is excretedin feces asthma attack information. Zafirlukast is not detected in urine asthma attack information.

In the pivotal bioequivalence study, the mean terminal half-life of zafirlukastis approximately 10 hours in both normal adult subjects and patients with asthma asthma attack information. In other studies, the mean plasma half-life of zafirlukast ranged from approximately8 to 16 hours in both normal subjects and patients with asthma asthma attack information. The pharmacokineticsof zafirlukast are approximately linear over the range from 5 mg to 80 mg asthma attack information. Steady-stateplasma concentrations of zafirlukast are proportional to the dose and predictablefrom single-dose pharmacokinetic data asthma attack information. Accumulation of zafirlukast in the plasmafollowing twice-daily dosing is approximately 45% asthma attack information.

The pharmacokinetic parameters of zafirlukast 20 mg administered as a singledose to 36 male volunteers are shown with the table below asthma attack information.

Mean (% Coefficient of Variation) pharmacokinetic
parameters of zafirlukast following single 20 mg
oral dose administration to male volunteers (n=36) C max
ng/mL t max h AUC
ng·h/mL t 1/2
h CL/f
L/h
326 (31.0) 2 (0.5-5.0) 1137 (34) 13.3 (75.6) 19.4 (32)
1 Median and range

Special Populations
Gender: The pharmacokinetics of zafirlukast are similar in males and females asthma attack information. Weight-adjusted apparent oral clearance does not differ due to gender asthma attack information.

Race: No differences in the pharmacokinetics of zafirlukast due to race havebeen observed asthma attack information.

Elderly: The apparent oral clearance of zafirlukast decreases with age asthma attack information. Inpatients above 65 years of age, there is an approximately 2-3 fold greater Cmax and AUC compared to young adult patients asthma attack information.

Children: Following administration of a single 20 mg dose of zafirlukast to20 boys and girls between 7 and 11 years of age, and in a second study, to 29boys and girls between 5 and 6 years of age, the following pharmacokinetic parameterswere obtained:

Parameter Children age
5-6 years
Mean (% Coefficient
of Variation) Children age
7-11 years
Mean (% Coefficient
of Variation)
C max (ng/mL) 756 (39%) 601 (45%)
AUC (ng·h/mL) 2458 (34%) 2027 (38%)
t max (h) 2.1 (61%) 2.5 (55%)
CL/f (L/h) 9.2 (37%) 11.4 (42%)

Weight unadjusted apparent clearance was 11.4 L/h (42%) in the 7-11 year oldchildren and 9.2 L/h (37%) in the 5-6 year old children, which resulted in greatersystemic drug exposures than that obtained in adults for an identical dose asthma attack information. To maintain similar exposure levels in children compared to adults, a dose of10 mg twice daily is recommended in children 5-11 years of age (see DOSAGE ANDADMINISTRATION ) asthma attack information.

Zafirlukast disposition was unchanged after multiple dosing (20 mg twice daily)in children and the degree of accumulation in plasma was similar to that observedin adults asthma attack information.

Hepatic Insufficiency: In a study of patients with hepatic impairment (biopsy-provencirrhosis), there was a reduced clearance of zafirlukast resulting in a 50-60%greater C max and AUC compared to normal subjects asthma attack information.

Renal Insufficiency: Based on a cross-study comparison, there are no apparentdifferences in the pharmacokinetics of zafirlukast between renally-impairedpatients and normal subjects asthma attack information.

Drug-Drug Interactions
The following drug interaction studies have been conducted with zafirlukast(see PRECAUTIONS , Drug Interactions ) asthma attack information.

Coadministration of multiple doses of zafirlukast (160 mg/day) to steady-statewith a single 25 mg dose of warfarin (a substrate of CYP2C9) resulted in a significantincrease in the mean AUC (+63%) and half-life (+36%) of S-warfarin asthma attack information. The meanprothrombin time increased by approximately 35% asthma attack information. The pharmacokinetics of zafirlukastwere unaffected by coadministration with warfarin asthma attack information.
Coadministration of zafirlukast (80 mg/day) at steady-state with a single doseof a liquid theophylline preparation (6 mg/kg) in 13 asthmatic patients, 18to 44 years of age, resulted in decreased mean plasma concentrations of zafirlukastby approximately 30%, but no effect on plasma theophylline concentrations wasobserved asthma attack information.
Coadministration of zafirlukast (20 mg/day) or placebo at steady-state witha single dose of sustained release theophylline preparation (16 mg/kg) in 16healthy boys and girls (6 through 11 years of age) resulted in no significantdifferences in the pharmacokinetic parameters of theophylline asthma attack information.
Coadministration of zafirlukast dosed at 40 mg twice daily in a single-blind,parallel-group, 3-week study in 39 healthy female subjects taking oral contraceptives,resulted in no significant effect on ethinyl estradiol plasma concentrationsor contraceptive efficacy asthma attack information.
Coadministration of zafirlukast (40 mg/day) with aspirin (650 mg four timesdaily) resulted in mean increased plasma concentrations of zafirlukast by approximately45% asthma attack information.
Coadministration of a single dose of zafirlukast (40 mg) with erythromycin (500mg three times daily for 5 days) to steady-state in 11 asthmatic patients resultedin decreased mean plasma concentrations of zafirlukast by approximately 40%due to a decrease in zafirlukast bioavailability asthma attack information.

dogs asthma treatment latex allergy policy & procedure how to treat asthma for athletes exercise and asthma symptom diary asthma infant pollen allergies adult asthma national allergy allergies of dogs allergy relief medicine control asthma info. about asthma spacers citric acid allergy asthma symtoms what are the biomedical causes of asthma copd asthma asthma plan citrus allergy teddy roosevelt asthma asthma articles astrazeneca accolate flow peak average normal expected fall allergies feline allergies food allergies in children fact sheet for asthma phosphate allergies asthma fact or fiction peanut butter allergies chiropractic neurology & asthma food allergies in children pet allergies symptom diary asthma infant allergy to water ragweed allergy vitamin c & allergies asthma symptons bombyx mori allergy in europe asthma chat room countries least affected by asthma asthma central heating quercetin asthma treatment air asthma signs symptoms of asthma symptoms of asthma alternaria allergy asthma symtoms b-d allergy syringe tray asthma advances+animal research asthma and wood heat number of deaths from asthma annually in usa adult onset asthma asthma triggers asthma diagram nccls & allergy asthma and ozone asthma strategic plans wheat allergies symptoms asthma symptoms allergy relief exercise induced asthma massage therapy and asthma allergy season latex allergy policy & procedure honey and allergies yeast allergy symptoms natural allergy remedy cats for people with allergies air sponge and absorbs odors and asthma skin allergy to laundry detergent

abilify abraxane accolate accupril accutane acetaminophen aciphex aclovate actifed activase actiza actonel actos aczone adacel adalat adderall adipex advair advate agilect albalon albuterol aldomet alesse aleve alimta allegra aloxi alphagan alprazolam altace altocor alvesco amaryl ambien amiodarone amitriptyline amoxicillin androgel angeliq anidulafungin antabuse antegren anusol apidra apokyn arthrotec asacol aspirin atenolol ativan augmentin avandia avapro avastin avelox axid

aasthma attack information assthma attack information astthma attack information asthhma attack information asthmma attack information asthmaa attack information asthma attack information asthma aattack information asthma atttack information asthma atttack information asthma attaack information asthma attacck information asthma attackk information asthma attack information asthma attack iinformation asthma attack innformation asthma attack infformation asthma attack infoormation asthma attack inforrmation asthma attack informmation asthma attack informaation asthma attack informattion asthma attack informatiion asthma attack informatioon asthma attack informationn sthma attack information athma attack information ashma attack information astma attack information astha attack information asthm attack information asthmaattack information asthma ttack information asthma atack information asthma atack information asthma attck information asthma attak information asthma attac information asthma attackinformation asthma attack nformation asthma attack iformation asthma attack inormation asthma attack infrmation asthma attack infomation asthma attack inforation asthma attack informtion asthma attack informaion asthma attack informaton asthma attack informatin asthma attack informatio a sthma attack information as thma attack information ast hma attack information asth ma attack information asthm a attack information asthma attack information asthma attack information asthma a ttack information asthma at tack information asthma att ack information asthma atta ck information asthma attac k information asthma attack information asthma attack information asthma attack i nformation asthma attack in formation asthma attack inf ormation asthma attack info rmation asthma attack infor mation asthma attack inform ation asthma attack informa tion asthma attack informat ion asthma attack informati on asthma attack informatio n asthma attack information sathma attack information atshma attack information ashtma attack information astmha attack information astham attack information asthm aattack information asthmaa ttack information asthma tatack information asthma attack information asthma atatck information asthma attcak information asthma attakc information asthma attac kinformation asthma attacki nformation asthma attack niformation asthma attack ifnormation asthma attack inofrmation asthma attack infromation asthma attack infomration asthma attack inforamtion asthma attack informtaion asthma attack informaiton asthma attack informatoin asthma attack informatino aasthma attack information theasthma attack information asthma attack information

a b c d e f g h i k l m n o p r s t u v w x z